Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D."

Transcription

1 Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease Toronto General Hospital Research Institute University Health Network (UHN)

2 HBV Recognition by Innate Immunity CD14/TLR-4 Historically, HBV seen as a stealth virus Not visible to innate sensing mdc CD14 Mounting evidence for HBV recognition Multiple pattern recognition receptors TLR-2 CD14/TLR-4 RIG-I cgas Cooper, J. Immunol. 175, (2005). Vanlandschoot, J. Gen. Virol (2002). van Montfoort, J. Virol. JVI (2016). Sato. Immunity 42, (2014). Cui. J. Virol. 90, (2015).

3 HBV Recognition by Innate Immunity CD14/TLR-4 mdc CD14 Recognition inflammation Evidence HBV can inhibit signaling HBV polymerase, X Caveat Transfection systems Stimuli was not HBV Restricted to hepatocytes PBMC not infected Infection systems may clarify Cooper, J. Immunol. 175, (2005). Vanlandschoot, J. Gen. Virol (2002). van Montfoort, J. Virol. JVI (2016). Sato. Immunity 42, (2014). Cui. J. Virol. 90, (2015).

4 Innate Immune Response in Chronic HBV Vertical transmission accounts for a majority of chronically infected patients Innate immune system is exposed to HBV before birth No longer any acute response to HBV because virus is always present Hong. Nat Comms 6, 1 12 (2015).

5 Innate Immune Response in Chronic HBV Innate immune system displays a regulatory role during chronic HBV infection Suppress anti-hbv immunity Regulate inflammation Innate immune cells dominate the immune composition of the liver

6 Innate Immune Regulation in Chronic HBV Myeloid-derived suppressor cells (MDSC) Expanded in chronic HBV patients IL-10 & arginase suppress T cells Kupffer cells produce IL-10 in response to HBV core antigen Mouse model Suppression of T cell immunity T cell NK cell TRAIL expression HBV-specific T cells express increased receptor for TRAIL NK-mediated depletion of HBV-specific T cells Pallett. Nat Med 21, (2015). Li. J. Immunol. 195, (2015). Peppa J. Exp Med. 210, (2013).

7 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

8 Blocking NK TRAIL-mediated killing of HBVspecific T cells. NK X TRAIL T Peppa J. Exp Med. 210, (2013).

9 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

10 Inducing presentation of the HBV antigen depot in monocytes CD14 MN GM-CSF + IL-4 6d Co-culture +/- Activation Monocyte-derived DC HBsAg-specific CD8 T cell 8/9 Healthy Chronic HBV HLA-mismatched A0201 Cw0801 Chronic HBV HLA-matched Gehring et al, J Clin Invest. 2013;123(9):

11 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

12 TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 TLR-8 NK & MAIT IL-12/18 IFN-γ NK bright MAIT IFN-γ TNF-α Jo et. al. PLoS Pathog Jun;10(6):e

13 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

14 TLR-7 mediated IFN-alpha production from plasmacytoid DC. GS-9620 TLR-7 IFN-α ISG15 mrna Gane J. Hepatol. 63, (2015).

15 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

16 NKT cell recognition of CD1d on infected hepatocytes. Baron. Immunity 16, (2002).

17 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

18 Blocking MDSC-mediated suppression Pallett. Nat Med 21, (2015).

19 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

20 Direct triggering of RIG-I in infected hepatocytes SB9200: Spring Bank Pharmaceutical RIG-I agonist Chronic Woodchuck Hepatitis Virus Infection model Korolowicz. PLoS ONE 11, e (2016).

21 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

22 CpG induction of imates TLR-9 TNF-α Huang et. al. Nat Immunol Apr 14;14(6):

23 Opportunities for Innate-targeted Immunotherapy Multiple mechanisms that can potentially be exploited Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).

24 Opportunities for Innate-targeted Immunotherapy Direct antiviral effect & potential environmental effect permit adaptive immunity Concern: Innate immunity is inherently non-specific Identify therapeutic window Effective intrahepatic immune response = inflammation Control/balance systemic toxicity Innate immunity is playing a significant regulatory role in chronic HBV What is regulating the regulators???? Understanding what is controlling the negative regulation by innate immunity may permit an organic immune response vs. therapeutic boosting.

MF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9

MF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9 SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab

More information

Cell-mediated Immunity

Cell-mediated Immunity Cellular & Molecular Immunology Cell-mediated Immunity Nicholas M. Ponzio, Ph.D. Department of Pathology & Laboratory Medicine April 6, 2009 Today s Presentation: Overview Cellular Interactions In Humoral

More information

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008

Immunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008 Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell

More information

The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease

The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease Int. J. Mol. Sci. 2014, 15, 4747-4779; doi:10.3390/ijms15034747 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms The Role of Chemokines in Hepatitis

More information

Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D

Hepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision

More information

Dendritische celtherapie bij melanoom

Dendritische celtherapie bij melanoom Radboud Institute for Molecular Life Sciences Dendritische celtherapie bij melanoom I. Jolanda M. de Vries Department of Tumor Immunology Radboud Institute for Molecular Life Sciences Radboud University

More information

Measles virus vaccine induces oncolysis of tumor cells and activates immune responses.

Measles virus vaccine induces oncolysis of tumor cells and activates immune responses. Measles virus vaccine induces oncolysis of tumor cells and activates immune responses. Marc Grégoire*, J.-F. Fonteneau, N. Boisgerault, J.-B. Guillerme and F. Tangy. * INSERM, Nantes, F-44, France. Pasteur

More information

Hepatitis C Virus and Cytokine Responses

Hepatitis C Virus and Cytokine Responses Hepatitis C Virus and Cytokine Responses Eui-Cheol Shin, M.D., Ph.D. Laboratory of Immunology & Infectious Diseases (LIID), Graduate School of Medical Science & Engineering (GSMSE), KAIST Daejeon, Korea

More information

Innate Immunity and Inflammation

Innate Immunity and Inflammation ISBTc Primer on Tumor Immunology and Biological Therapy of Cancer Innate Immunity and Inflammation Willem Overwijk, Ph.D. MD Anderson Cancer Center Center for Cancer Immunology Research Houston, TX www.allthingsbeautiful.com

More information

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s) TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,

More information

Can HPV, cervical neoplasia or. HIV transmission?

Can HPV, cervical neoplasia or. HIV transmission? Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical

More information

System Biology analysis of innate and adaptive immune responses during HIV infection

System Biology analysis of innate and adaptive immune responses during HIV infection System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,

More information

The Adaptive Immune Responses

The Adaptive Immune Responses The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start

More information

TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD

TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD Abstract #1527O TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD M. Thomas, S. Ponce-Aix, A. Navarro Mendivil,

More information

Innate and adaptive immunity have evolved

Innate and adaptive immunity have evolved Immune Response in Hepatitis B Virus Infection Anthony Tan 1, Sarene Koh 2, and Antonio Bertoletti 1,2,3 1 Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore 169857 2 Viral

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection

Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection 1 Evolution, Medicine, and Public Health [2014] pp. 1 9 doi:10.1093/emph/eot023 commentary Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection Brook G. Warner

More information

La risposta immune all infezione da virus ebola. Chiara Agrati, PhD

La risposta immune all infezione da virus ebola. Chiara Agrati, PhD La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

JPEMS Nantes, Basic Immunology INNATE IMMUNITY

JPEMS Nantes, Basic Immunology INNATE IMMUNITY JPEMS Nantes, 2014- Basic Immunology INNATE IMMUNITY Teacher: Pr. Régis Josien, Laboratoire d Immunologie and INSERM U1064, CHU Nantes Regis.Josien@univ-nantes.fr 1 Contents 1. General features and specificity

More information

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer

More information

THE IMMUNOPATHOGENESIS AND TREATMENT OF SEZARY SYNDROME ALAIN H. ROOK, M.D. PERELMAN SCHOOL OF MEDICINE UNIVERSITY OF PENNSYLVANIA

THE IMMUNOPATHOGENESIS AND TREATMENT OF SEZARY SYNDROME ALAIN H. ROOK, M.D. PERELMAN SCHOOL OF MEDICINE UNIVERSITY OF PENNSYLVANIA THE IMMUNOPATHOGENESIS AND TREATMENT OF SEZARY SYNDROME ALAIN H. ROOK, M.D. PERELMAN SCHOOL OF MEDICINE UNIVERSITY OF PENNSYLVANIA High Clinical Response Rates Using Multimodality Immune Therapy

More information

MAJOR ARTICLE. Hepatitis B; combination therapy; interferon alfa; NK cells; innate immunity; TRAIL.

MAJOR ARTICLE. Hepatitis B; combination therapy; interferon alfa; NK cells; innate immunity; TRAIL. MAJOR ARTICLE Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated

More information

Horizon 2020 Programme. SFS-01b Tackling losses from terrestrial animal diseases

Horizon 2020 Programme. SFS-01b Tackling losses from terrestrial animal diseases Horizon 2020 Programme SFS-01b-2014 Tackling losses from terrestrial animal diseases Strengthening Animal Production and Health through the Immune Response Project ID: 633184 D12.1 Age related innate responses

More information

Impact of TLR7/8 Triggering on HIV Pathogenesis

Impact of TLR7/8 Triggering on HIV Pathogenesis University Hospital Zurich u Division of Infectious Diseases and Hospital Epidemiology Impact of TLR7/8 Triggering on HIV Pathogenesis Roberto F. Speck, MD Hallmark of HIV-Infection is the Progressive

More information

Richard S. Kornbluth, M.D., Ph.D.

Richard S. Kornbluth, M.D., Ph.D. Treatment of established tumors with peritumoral injections of CD40 ligand (CD40L), CpG, poly(i:c), and extracellular ATP in murine models Richard S. Kornbluth, M.D., Ph.D. Disclosure: Richard Kornbluth

More information

Ahmad A. Tarhini, MD, PhD. BS in Biology, American University of Beirut, Doctor of Medicine, Kaunas University of Medicine, 1999

Ahmad A. Tarhini, MD, PhD. BS in Biology, American University of Beirut, Doctor of Medicine, Kaunas University of Medicine, 1999 Overcoming Melanoma Immune Tolerance: Non-specific CTLA-4 Blockade/Interferon-α and Antigen Specific Immunization with TLR-9 Stimulation/Local GM-CSF as Components of a Melanoma Immunotherapeutic Strategy

More information

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive

More information

HBV Cure Definition and New Drugs in Development

HBV Cure Definition and New Drugs in Development HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada

More information

Generation of monocytederived Dendritic Cells (modcs)

Generation of monocytederived Dendritic Cells (modcs) monocytederived Dendritic (modcs) Application Note Background Dendritic (DCs) are so called because of their characteristic cell surface projections that resemble the dendrites of neurons (see Fig 1 and

More information

New HBV Treatment Options on the Horizon

New HBV Treatment Options on the Horizon New HBV Treatment Options on the Horizon Harry L.A. Janssen Director of Liver Clinic Toronto Western & General Hospitals University of Toronto, Canada Erasmus University Medical Center Rotterdam, The Netherlands

More information

Posters and Presentations

Posters and Presentations Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association

More information

Innate Immunity. Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016

Innate Immunity. Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016 Innate Immunity Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016 Objectives: Explain how innate immune system recognizes foreign substances

More information

Significance of the MHC

Significance of the MHC CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmunity Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmune disease can be caused to primary defects in B cells, T cells and possibly

More information

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center

Cytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,

More information

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity

More information

Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?

Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? Abbas Chapter 2: Sarah Spriet February 8, 2015 Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? a. Dendritic cells b. Macrophages c. Monocytes

More information

The Basic Science Behind the Potent New Immunotherapies

The Basic Science Behind the Potent New Immunotherapies The Basic Science Behind the Potent New Immunotherapies isbt November 11, 25 Nicholas P. Restifo, MD Principal Investigator Goal: To develop new immunotherapies for patients with cancer Strategy: create

More information

SUPPLEMENTAL MATERIAL: CLINICAL ASPECTS OF inkt CELL BIOLOGY

SUPPLEMENTAL MATERIAL: CLINICAL ASPECTS OF inkt CELL BIOLOGY SUPPLEMENTAL MATERIAL: CLINICAL ASPECTS OF inkt CELL BIOLOGY Injection of α-galcer in Phase I Clinical Trials The first in-human study was a Phase I trial using intravenous injection of α-galcer at a range

More information

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures

More information

Effector T Cells and

Effector T Cells and 1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New

More information

Lecture on Innate Immunity and Inflammation

Lecture on Innate Immunity and Inflammation Lecture on Innate Immunity and Inflammation Evolutionary View Epithelial barriers to infection Four main types of innate recognition molecules:tlrs, CLRs, NLRs, RLRs NF-κB, the master transcriptional regulator

More information

Disease causing organisms Resistance Immunity

Disease causing organisms Resistance Immunity Part 1 Disease causing organisms Resistance Immunity Bacteria Most common pathogens Anthrax Cholera Staphylococcus epidermidis bacteria Bacterial diseases Tuberculosis Cholera Bubonic Plague Tetanus Effects

More information

Paediatrica Indonesiana Vol. 41 No. 7-8, July-August 2001 Paediatrica Indonesiana Paediatr Indones 2001; 41:

Paediatrica Indonesiana Vol. 41 No. 7-8, July-August 2001 Paediatrica Indonesiana Paediatr Indones 2001; 41: 208 Paediatrica Indonesiana Vol. 41 No. 7-8, July-August 2001 Paediatrica Indonesiana Paediatr Indones 2001; 41:208-213 Special article Immunological aspects of persistent hepatitis B in children Harsoyo

More information

Cancer Vaccine Immunotherapy

Cancer Vaccine Immunotherapy Cancer Vaccine Immunotherapy Jay A. Berzofsky, M.D., Ph.D. Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA Institute of Medicine National Cancer Policy

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

HBV: Current and Emerging Therapies

HBV: Current and Emerging Therapies HBV: Current and Emerging Therapies Just in: Highlights from EASL 2013 Jordan J. Feld, MD, MPH Assistant Professor of Medicine Toronto Western Hospital McLaughlin-Rotman Centre for Global Health Outline

More information

IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN

IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN IMMUNOMODULATORY PROPERTIES OF INTERFERON ALPHA AND RIBAVIRIN Nikolai V. Naoumov UCL Institute of Hepatology University College London 69-75 Chenies Mews London WC1E 6HX UK E-mail: n.naoumov@ucl.ac.uk

More information

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through

More information

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples

Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples Simple automated manufacturing of gene engineered T cells from lymphoma and melanoma blood samples ISCT North America 216 Regional Meeting Nadine Mockel-Tenbrinck Miltenyi Biotec GmbH Macrophage Tumour

More information

Role of Innate Immunity in Control of Adaptive Immunity

Role of Innate Immunity in Control of Adaptive Immunity Role of Innate Immunity in Control of Adaptive Immunity Innate Immunity The burden of pathogen sensing is placed on the innate immune system Danger hypothesis Missing Self Based on the detection of molecular

More information

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board

HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest

More information

Felix Yarovinsky. Department of Immunology, UT Southwestern Medical Center. Innate immune defense to Toxoplasma gondii

Felix Yarovinsky. Department of Immunology, UT Southwestern Medical Center. Innate immune defense to Toxoplasma gondii Felix Yarovinsky Department of Immunology, UT Southwestern Medical Center Innate immune defense to Toxoplasma gondii Pathogen recognition by innate immune cells Pathogen Parasites Viruses Bacteria Initiator

More information

Hepatitis C Cure The Invisible Epidemic

Hepatitis C Cure The Invisible Epidemic Hepatitis C Cure The Invisible Epidemic Iris House 8 Th Annual Face of AIDS Summit Hadiyah Charles Hepatitis Advocacy Manager Harm Reduction Coalition Hepatitis C Basics A virus that can cause chronic

More information

Inflammatory macrophages and dendritic cells guiding cancer manifestation

Inflammatory macrophages and dendritic cells guiding cancer manifestation Inflammatory macrophages and dendritic cells guiding cancer manifestation E. Marion Schneider 1, David Zielberg 2, Haouraa Mostafa 1, Karl Aigner 3, Andrej Pala 4, Michael Georgieff 5, C Rainer Wirtz 4,

More information

Tumor Immunology. Tumor (latin) = swelling

Tumor Immunology. Tumor (latin) = swelling Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to

More information

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis

Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Author's response to reviews Title:Identification of a novel microrna signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis Authors: Mei-Yin Zhang (zhangmy@sysucc.org.cn) Shu-Hong

More information

Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques

Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate

More information

The destiny of natural killer cells in the tumor microenvironment: To be suppressed or activated?

The destiny of natural killer cells in the tumor microenvironment: To be suppressed or activated? From The Department of Oncology-Pathology Karolinska Institutet, Stockholm, Sweden The destiny of natural killer cells in the tumor microenvironment: To be suppressed or activated? Dhifaf Sarhan Stockholm

More information

T cells III: Cytotoxic T lymphocytes and natural killer cells

T cells III: Cytotoxic T lymphocytes and natural killer cells T cells III: Cytotoxic T lymphocytes and natural killer cells Margrit Wiesendanger Division of Rheumatology, CUMC September 17, 2008 Killer cells: CD8 + T cells (adaptive) vs. natural killer (innate) Shared

More information

B F. Location of MHC class I pockets termed B and F that bind P2 and P9 amino acid side chains of the peptide

B F. Location of MHC class I pockets termed B and F that bind P2 and P9 amino acid side chains of the peptide Different MHC alleles confer different functional properties on the adaptive immune system by specifying molecules that have different peptide binding abilities Location of MHC class I pockets termed B

More information

Tumor Immunotherapy. Sarah Adams, MD August 4, 2014

Tumor Immunotherapy. Sarah Adams, MD August 4, 2014 Tumor Immunotherapy Sarah Adams, MD August 4, 2014 Objectives Development of immune therapy for cancer T cell therapies Dendritic cell therapies Checkpoint blockade Immunomodulation by chemotherapeutics

More information

Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic

Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic isbtc 10-13 November 2005 Valeria Milani, MD, PhD Munich Agenda 1. NK ligands

More information

Additional file 6. Summary of experiments characterizing development of adaptive immune response

Additional file 6. Summary of experiments characterizing development of adaptive immune response Additional file 6. Summary of experiments characterizing development of adaptive immune response Tests performed to evaluate the development of adaptive immunity in patients are summarized in Table 1.

More information

BALANCE BETWEEN ESTROGENS AND PROINFLAMMATORY CYTOKINES REGULATES CHEMOKINE PRODUCTION INVOLVED IN THYMIC GERMINAL CENTER FORMATION

BALANCE BETWEEN ESTROGENS AND PROINFLAMMATORY CYTOKINES REGULATES CHEMOKINE PRODUCTION INVOLVED IN THYMIC GERMINAL CENTER FORMATION BALANCE BETWEEN ESTROGE AND PROINFLAMMATORY CYTOKINES REGULATES CHEMOKINE PRODUCTION INVOLVED IN THYMIC GERMINAL CENTER FORMATION Nadine Dragin 1, 2, 3,, Patrice Nancy 4, José Villegas 2, 3, 5, Régine

More information

Allergology & Clinical Immunology Lyon

Allergology & Clinical Immunology Lyon Allergology & Clinical Immunology Lyon Audrey NOSBAUM Marc VOCANSON Aurore ROZIERES Benoit BEN-SAID Frédéric BERARD Equipe 14 INSERM U1111 Catherine GOUJON Service Allergologie et Immunologie Clinique

More information

Lecture on Innate Immunity and Inflammation. Innate Immunity: An Evolutionary View

Lecture on Innate Immunity and Inflammation. Innate Immunity: An Evolutionary View Lecture on Innate Immunity and Inflammation Evolutionary View Epithelial barriers to infection Four main types of innate recognition molecules:tlrs, CLRs, NLRs, RLRs NF-κB, the master transcriptional regulator

More information

Immunoadjuvant Properties of Oncolytic Schwarz Measles Virus

Immunoadjuvant Properties of Oncolytic Schwarz Measles Virus Immunoadjuvant Properties of Oncolytic Schwarz Measles Virus Dr Jean-François Fonteneau Institut de Recherche en Santé de l Université de Nantes INSERM UMR892, CNRS UMR6299 Nantes, France Anti-tumor Virotherapy

More information

Significance of the MHC

Significance of the MHC CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ

More information

Our T cell epitope test service offers you:

Our T cell epitope test service offers you: Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made

More information

ANTI-C5AR ACQUISITION

ANTI-C5AR ACQUISITION KIR2DL1,2,3 NKG2A NKP46 KIR3DL2 MICA/B CD73 CD39 ANTIC5AR ACQUISITION JUNE 2017 NOVEL CHECKPOINTS IN IMMUNOONCOLOGY Page 2 FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A.

More information

Are booster immunisations needed for lifelong hepatitis B immunity?

Are booster immunisations needed for lifelong hepatitis B immunity? Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support

More information

Intestinal Microflora and Immunoregulation

Intestinal Microflora and Immunoregulation Intestinal Microflora and Immunoregulation Monica Boirivant Istituto Superiore di Sanità Roma Microflora-immune cells interactions Ethanol AT 12 T Effect of ir Ethanol 5% administration 115 weight (% of

More information

IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients

IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a Phase 2a trial A. B. Kimball 1, J. Krueger 2, T. Sullivan

More information

2. Innate immunity 2013

2. Innate immunity 2013 1 Innate Immune Responses 3 Innate immunity Abul K. Abbas University of California San Francisco The initial responses to: 1. Microbes: essential early mechanisms to prevent, control, or eliminate infection;

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response

CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response Francesco Parlati, Ph.D. Calithera Biosciences South San Francisco, CA Arginine Depletion by Arginase

More information

Innate Immunity. Jan 8 th Prof. dr. sc. Ivana Novak Nakir 1

Innate Immunity. Jan 8 th Prof. dr. sc. Ivana Novak Nakir 1 Innate Immunity Jan 8 th 2018. Prof. dr. sc. Ivana Novak Nakir 1 Adaptive Innate 2 Immune system overview 1 st line of defense skin (2m 2 ) and mucosal membranes (~400m 2 ): physical barrier, lymphoid

More information

How Reactive Metabolites Induce an Immune Response that Sometimes Leads to an Idiosyncratic Drug Reaction

How Reactive Metabolites Induce an Immune Response that Sometimes Leads to an Idiosyncratic Drug Reaction How Reactive Metabolites Induce an Immune Response that Sometimes Leads to an Idiosyncratic Drug Reaction Jack Uetrecht, M.D., Ph.D. jack.uetrecht@utoronto.ca It is very difficult to study the mechanisms

More information

Isolated Hepatitis B Core Antibody

Isolated Hepatitis B Core Antibody NORTHWEST AIDS EDUCATION AND TRAINING CENTER Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014 Isolated Core Antibody Virology & terminology Definition

More information

Humoral and cellular immune responses to modified hepatitis B plasmid DNA vaccine in mice

Humoral and cellular immune responses to modified hepatitis B plasmid DNA vaccine in mice Tropical Journal of Pharmaceutical Research April 2016; 15 (4): 687-693 ISSN: 1596-5996 (print); 1596-9827 (electronic) Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001

More information

Fanconi Anemia: immune deficiency and susceptibility to cancer

Fanconi Anemia: immune deficiency and susceptibility to cancer Instituto de Bioquímica Médica (Laboratório de Imunologia Tumoral e Laboratório de Biologia molecular e Instituto de Ciências Biomédicas/UFRJ Centro de Transplante de Medula Óssea Hospital de Clínicas

More information

The Journal of International Medical Research 2011; 39:

The Journal of International Medical Research 2011; 39: The Journal of International Medical Research 211; 39: 1381 1391 Increased Circulating Immunosuppressive CD14 + HLA-DR /low Cells Correlate with Clinical Cancer Stage and Pathological Grade in Patients

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with

More information

Innate Immunity. By Dr. Gouse Mohiddin Shaik

Innate Immunity. By Dr. Gouse Mohiddin Shaik Innate Immunity By Dr. Gouse Mohiddin Shaik Types of immunity Immunity Innate / inborn Non-specific Acquired / adaptive Specific 3rd line of defense Physical barriers Skin, Saliva, Mucous, Stomach acid,

More information

Living in the liver: hepatic infections

Living in the liver: hepatic infections Living in the liver: hepatic infections Ulrike Protzer 1, Mala K. Maini 2 and Percy A. Knolle 3 Abstract The liver has vital metabolic and clearance functions that involve the uptake of nutrients, waste

More information

Chapter 24 The Immune System

Chapter 24 The Immune System Chapter 24 The Immune System The Immune System Layered defense system The skin and chemical barriers The innate and adaptive immune systems Immunity The body s ability to recognize and destroy specific

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma

Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma Int J Clin Exp Med 2014;7(4):1175-1179 www.ijcem.com /ISSN:1940-5901/IJCEM0000102 Letter to Editor Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma

More information

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural

More information

Immune Cells in Regional Adipose Tissue Depots: A Pilot Study. Vi Dam. A Thesis. The Department. Exercise Science

Immune Cells in Regional Adipose Tissue Depots: A Pilot Study. Vi Dam. A Thesis. The Department. Exercise Science Effect of Early onset Obesity versus Late onset Obesity on Immune Cells in Regional Adipose Tissue Depots: A Pilot Study Vi Dam A Thesis in The Department of Exercise Science Presented in Partial Fulfillment

More information

Development of live attenuated pediatric RSV vaccines

Development of live attenuated pediatric RSV vaccines Development of live attenuated pediatric RSV vaccines Laboratory of Infectious Diseases, NIAID, NIH (Ursula Buchholz, Peter Collins) Center for Immunization Research, JHU (Ruth Karron) Infant with RSV

More information

Basic immunology. Lecture 9. Innate immunity: inflammation, leukocyte migration. Péter Engelmann

Basic immunology. Lecture 9. Innate immunity: inflammation, leukocyte migration. Péter Engelmann Basic immunology Lecture 9. Innate immunity: inflammation, leukocyte migration Péter Engelmann Different levels of the immune response Recognition molecules of innate immunity Initiation of local and systemic

More information

STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)

STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating

More information